Feasibility Study of Use and Acceptability of New Clear Communication of Lab Test Results (CCLR) Letter for Older Adults
Embedding Health Literacy Best Practices: A Feasibility Study Using the Clear Communication of Laboratory Test Results (CCLR) Template
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Medical School
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 70 or older
- English fluency
- order for CBC, BMP, or FLP
- capacity to provide informed consent
- willingness to participate in follow-up phone survey
Exclusion Criteria:
- provider determined potential participant does not have cognitive capacity to read or understand communication about lab test results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Participants received the standard communication letter for result of blood test
Providers send their usual result note related to a blood test
|
|
|
Experimental: Clear Communication of Lab Test Result letter
Participants received the results of their blood test on the Clear Communication of Lab Test Results (CCLR) letter
|
The Clear Communication of Lab Test Result letter (CCLR) was designed using clear communication and health literacy best practices to explain test done, meaning of results, and any future action recommended.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment
Time Frame: 18 months
|
Investigators will recruit participants for the study and providers will use the Clear Communication of Lab Test Result Letter
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Anxiety-Visual Scale
Time Frame: 2 weeks after blood test was drawn
|
Measure of anxiety after receiving the lab result letter.
The minimum value is zero (0) and the maximum value is 100; higher scores mean greater anxiety.
|
2 weeks after blood test was drawn
|
|
Confidence
Time Frame: 2 weeks after blood test was drawn
|
Visual analogue scale to assess confidence in understanding meaning of lab test result.
The minimum score is 1 (not at all satisfied) and the maximum score is 10 (extremely satisfied).
Higher score reflects higher confidence.
|
2 weeks after blood test was drawn
|
|
Comprehension of follow-up plans
Time Frame: 2 weeks after blood test was drawn
|
Yes/No response to question, Was it clear if there were any next steps participant needs to do related to the blood test results?
|
2 weeks after blood test was drawn
|
|
Patient Satisfaction
Time Frame: 2 weeks after blood test was drawn
|
Visual analogue scale response to question, how satisfied was the participant with the letter describing lab test results?
Minium response is one (1) not at all satisfied and the maximum response is 10, extremely satisfied.
A higher score reflects higher satisfaction.
|
2 weeks after blood test was drawn
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nancy Morris, PhD, RN, ANP-BC, University of Massachusetts, Worcester
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 00000965
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.